Alli (previously Orlistat GSK) (orlistat)
- Region
- 🇪🇺 EU
- Active substance
- orlistat
- Company
- Haleon Ireland Dungarvan Limited
- Status
- Authorised
- Therapeutic area
- Obesity
- CHMP opinion
- Thu 24 May 2007
- EU approval
- Sun 22 Jul 2007
- Application
- EMEA/H/C/000854
- ATC
- A08AB01
- Official record
- www.ema.europa.eu
Indication
Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Xenical Authorised · CHEPLAPHARM Arzneimittel GmbH
Follow Alli (previously Orlistat GSK)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.